Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Genedrive revenues rise as it waits for EU approval

Genedrive’s HCV assay provides on-the-spot results in just 90 minutes direct from a very small plasma sample.
picture of Genedrive device
Test results come back within 90 minutes

Genedrive PLC (LON:GDR) boosted revenues by 45% in its latest half year as it prepares for the launch of its hepatitis C test once it gets an award of CE mark.

The receipt of CE IVD certification under the EU Medical Devices Directive would green-light the commercialisation of the product in the European Union.

Genedrive’s HCV assay provides on-the-spot results in just 90 minutes direct from a very small plasma sample.

Revenues in the half year to December rose to £2.9mln (£2mln), with sales related to Genedrive up 71% to £1.2mln.

Investment in the hand-held device, however, meant losses of £2.7mln in the year. The company had cash at the period-end of £5.7mln.

David Budd, Genedrive’s chief executive, said: "The recent period has seen genedrive plc continue to focus on the significant opportunity we see in molecular diagnostics with our rapid, point of need Genedrive system.

“In Hepatitis C, we are making very positive progress. Our recent application for CE certification positions us well to be first to market with a decentralised point of need HCV qualitative test which would enable real-time treatment and management of chronic HCV patients with the new generation of direct acting antivirals. 

"Despite the difficulties in accessing the full potential of the Genedrive system thus far through the MTB/RIF launch, the Board remains confident of the business strategy. “

View full GDR profile View Profile

Genedrive PLC Timeline

Related Articles

Paradigm Biopharmaceuticals: Access latest PPT from Proactive's CEO Sessions
May 18 2017
Paul Rennie talked timeline to clinical trial results with investors.
Proteomics International Laboratories: Access latest PPT from Proactive's CEO Sessions
April 13 2017
Richard Lipscombe talked revenue generation and growth path with investors.
Regeneus: Access latest PPT from Proactive's CEO Sessions
June 18 2017
John Martin discussed regenerative medicine with investors.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use